Asahi Kasei Therapeutics
secondary
spacer
Corporate Profile##outline
In the U.S., Asahi Kasei Therapeutics sells an immunosuppressive drug using proprietary drug delivery technology* to help prevent organ rejection after kidney transplants. The company is enhancing licensing activity to obtain new pharmaceuticals as growth drivers to accelerate the Asahi Kasei Group’s transformation to a global healthcare enterprise. In September 2026, the company name Veloxis Pharmaceuticals was changed to Asahi Kasei Therapeutics, unifying the brand of the main pharmaceutical operations in Japan, the U.S., and Europe.
* Technology to enhance the effects and/or reduce the side effects of drugs by controlling their absorption, distribution, metabolism, and excretion
1
spacer
column-header
Trade name
Asahi Kasei Therapeutics Inc.
https://www.aktx.com/
https://www.aktx.com/
Main businesses
Research, development, manufacture, and sale of pharmaceuticals for organ transplantation
Home office
2000 Regency Parkway, Suite 500, Cary, NC 27518, USA
President
Stacy G. Wheeler
Paid-in capital
US$1,117 million (including capital surplus)
Shareholder
Asahi Kasei Corp.
Phone
+1-919-591-3090
(as of September 30, 2026)
Officers##officer
column-header
Stacy G. Wheeler
Chief Executive Officer, Board Director
Yoshikazu Aoki
Board Director
Ken Shinomiya
Board Director
Fredrik Johansson
Executive Officer
Chief Financial Officer
Chief Financial Officer
Carl Kraus
Executive Officer
Chief Medical Officer
Chief Medical Officer
Ed Sleeper
Executive Officer
Chief Ethics and Compliance Officer
Chief Ethics and Compliance Officer
V. Noel Barnard
Executive Officer
Vice President, Legal and General Counsel; Secretary
Vice President, Legal and General Counsel; Secretary
Neil Morton
Executive Officer
Vice President, Global Business Development
Vice President, Global Business Development
(as of April 1, 2026)
column-header
column-header
column-header
column-header
column-header